Literature DB >> 12052036

The fatty acid amide hydrolase (FAAH).

D G Deutsch1, N Ueda, S Yamamoto.   

Abstract

The fatty acid amide hydrolase (FAAH), is the enzyme responsible for the hydrolysis of anandamide, an endocannabinoid. The FAAH knockout, the assays for FAAH, the activity of its substrates, its reversibility and its cloning from rat, mouse, human, and pig are covered in this review. The conserved regions of FAAH are described in terms of sequence and function, including the domains that contains the serine catalytic nucleophile, the hydrophobic domain important for self-association, the proline rich domain region which may be important for subcellular localization and the fatty acid chain binding domain. The FAAH mouse promoter region was characterized in terms of its transcription start site and its activity in different cell types. The distribution of FAAH in the major organs in the body is described as well as regional distribution in the brain and its correlation with cannabinoid receptors. Since FAAH is recognized as a drug target, a large number of inhibitors have been synthesized and tested since 1994 and these are reviewed in terms of reversibility, potency, and specificity for FAAH. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052036     DOI: 10.1054/plef.2001.0358

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  48 in total

1.  Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.

Authors:  N P Bowles; M N Hill; S M Bhagat; I N Karatsoreos; C J Hillard; B S McEwen
Journal:  Neuroscience       Date:  2011-09-10       Impact factor: 3.590

Review 2.  The endocannabinoid system: a general view and latest additions.

Authors:  Luciano De Petrocellis; Maria Grazia Cascio; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

Review 3.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

4.  Clickable, photoreactive inhibitors to probe the active site microenvironment of fatty acid amide hydrolase().

Authors:  Susanna M Saario; Michele K McKinney; Anna E Speers; Chu Wang; Benjamin F Cravatt
Journal:  Chem Sci       Date:  2011-08-11       Impact factor: 9.825

5.  Tempo and mode in the endocannaboinoid system.

Authors:  John M McPartland; Ryan W Norris; C William Kilpatrick
Journal:  J Mol Evol       Date:  2007-08-04       Impact factor: 2.395

Review 6.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

7.  N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.

Authors:  Kazuhito Tsuboi; Christine Hilligsmann; Séverine Vandevoorde; Didier M Lambert; Natsuo Ueda
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

8.  Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

Authors:  D Proudnikov; T Kroslak; J C Sipe; M Randesi; D Li; S Hamon; A Ho; J Ott; M J Kreek
Journal:  Pharmacogenomics J       Date:  2009-12-15       Impact factor: 3.550

Review 9.  Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids.

Authors:  Matthew N Hill; Bruce S McEwen
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-11-10       Impact factor: 5.067

10.  Functional disassociation of the central and peripheral fatty acid amide signaling systems.

Authors:  Benjamin F Cravatt; Alan Saghatelian; Edward G Hawkins; Angela B Clement; Michael H Bracey; Aron H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.